Previous 10 | Next 10 |
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw....
Wedbush has downgraded Y-mAbs Therapeutics ( NASDAQ: YMAB ) to neutral following a US FDA panel's unanimously decision Friday to reject omburtamab for pediatric neuroblastoma. The firm cut its price target to $6 from $21 (~33% downside based on Friday's close). Ana...
Summary Shares have lost 45% in 2022 and are down by 58% since my 2019 article. Conservative peak sales estimate of $200M for Danyelza contrasts favorably to current enterprise value of $260M. SADA technology intends to greatly increase therapeutic index of radiopharmace...
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...
An expert panel of the FDA unanimously voted against approving the marketing application submitted by Y-mAbs Therapeutics, Inc. ( NASDAQ: YMAB ) for omburtamab, an experimental therapy for rare cancer neuroblastoma. On the question of "Has Applicant provided sufficient evi...
New York, New York--(Newsfile Corp. - October 27, 2022) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") common stock (NASDAQ: YMAB). Y-mAbs is developing omburtamab, which is used to treat ch...
Despite US FDA briefing documents released Wednesday expressing concerns about efficacy for Y-mAbs Therapeutics' ( NASDAQ: YMAB ) omburtamab for neuroblastoma, Citi is confident the candidiate can win approval. Shares are down 19% in Thursday afternoon tr...
BOSTON , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn more about how t...
US FDA scientists are concerned that data submitted in support of Y-mAbs' Therapuetics ( NASDAQ: YMAB ) Biologics License Application for its neuroblastoma therapy omburtamab does not provide substantial evidence of efficacy. In briefing documents posted Wednesday in adv...
NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the t...
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...